Editas Medicine
11 Hurley Street
Cambridge
MA
02141
United States
Tel: 617 401 9000
Website: https://www.editasmedicine.com/
Email: info@editasmed.com
About Editas Medicine
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Stock Symbol: EDIT
Stock Exchange: NASDAQ
247 articles about Editas Medicine
-
Five weeks after taking the reins as CEO of CRISPR-focused Editas Medicine, Gilmore O’Neill fulfilled his first task, appointing a new chief medical officer.
-
Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.
-
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
6/7/2022
Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, “Editas Medicine”), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta Treatment for cancer.
-
Editas Medicine Reports Inducement Grants to New Chief Executive Officer
6/6/2022
Editas Medicine, Inc. announced the grant of inducement awards to the Company’s newly appointed President and Chief Executive Officer, Gilmore O’Neill, M.B., M.M.Sc.
-
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
5/18/2022
Editas Medicine, Inc., a leading genome editing company, will present data later on its SLEEK gene editing technology during the New Gene Editing Technologies and Applications Session at the 25th Annual Meeting of the American Society of Gene and Cell Therapy being held in Washington, D.C., and virtually, May 16 – 19, 2022.
-
U.S. Food and Drug Administration(FDA) has granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.
-
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta ThalassemiaCompany on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end
5/12/2022
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing medicine, for the treatment of beta thalassemia.
-
Editas Medicine Announces First Quarter 2022 Results and Business Updates
5/4/2022
Editas Medicine, Inc., a leading genome editing company, reported business highlights and financial results for the first quarter of 2022.
-
Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting
5/2/2022
Editas Medicine, Inc. announced that four abstracts have been accepted for presentation, including three oral presentations, at the 25th Annual Meeting of the American Society of Gene and Cell Therapy being held in Washington, D.C., and virtually, May 16 – 19, 2022.
-
Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update
4/27/2022
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for the first quarter of 2022.
-
Editas Medicine snagged Rare Pediatric Disease designation for its experimental beta thalassemia gene therapy, while VBL received Fast Track designation for an ofra-vec combination in ovarian cancer.
-
Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia
4/26/2022
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia.
-
O’Neill, who has served as chief medical officer at Sarepta Therapeutics since 2018, said he is excited about the potential of Editas’ pipeline.
-
Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer
4/14/2022
Editas Medicine, Inc. today announced that its Board of Directors has appointed Dr. Gilmore O’Neill, M.B., M.M.Sc., as President and Chief Executive Officer.
-
Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10
4/11/2022
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the administration of EDIT-101, an experimental CRISPR gene editing medicine, to the first pediatric patient enrolled in the BRILLIANCE clinical trial, which is designed to test the safety of EDIT-101 for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.
-
The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to Broad, not UC Berkeley.
-
Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference
2/28/2022
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to the Broad Institute, Inc. (Broad) involving specific patents for CRISPR/Cas9 editing in human cells.
-
Three genome editing companies, Intellia Therapeutics, Editas Medicine and uniQure, are each anticipating a bright 2022 as the promises of gene therapy continue to be realized.
-
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
2/24/2022
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2021.
-
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update
2/16/2022
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results for the fourth quarter and full year 2021.